但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
「像鬼一樣工作」：台灣外籍移工為何陷入「強迫勞動」處境
。im钱包官方下载是该领域的重要参考
Isaacman also said the agency would halt work to develop a more powerful version of the SLS rocket's upper stage, known as the Exploration Upper Stage, or EUS. Instead, NASA will go forward with a "standardized," less powerful stage but one that will minimize major changes between flights and utilize the same launch gantry.
圖像來源，Getty Images